Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta-analysis.

Autor: Tsai TF; Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan., Tada Y; Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan., Kung C; Global Medical Affairs, Bristol Myers Squibb, Taipei, Taiwan., Zhong Y; Worldwide HEOR, Bristol Myers Squibb, Princeton, New Jersey, USA., Cichewicz A; Evidera, Evidence Synthesis, Modeling and Communication, Waltham, Massachusetts, USA., Borkowska K; Evidence Synthesis, Modeling and Communication, PPD Poland, Warsaw, Poland., Westley T; Evidera, Evidence Synthesis, Modeling and Communication, Waltham, Massachusetts, USA., Kisa RM; Bristol Myers Squibb, Princeton, New Jersey, USA., Huang YH; Department of Dermatology, Chang Ghang Memorial Hospital and Chang Gung University, Taoyuan, Taiwan.; Department of Dermatology, First Hospital of China Medical University, Shenyang, China., Gao XH; Department of Dermatology, First Hospital of China Medical University, Shenyang, China., Jo SJ; Department of Dermatology, Seoul National University College of Medicine, Seoul, South Korea., Armstrong AW; Department of Medicine, University of California Los Angeles, Los Angeles, California, USA.

Publikováno v: The Journal of dermatology [J Dermatol] 2024 Nov 11. Date of Electronic Publication: 2024 Nov 11.

Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials.

Autor: Korman NJ; Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, Cleveland, OH, USA., Warren RB; Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UK.; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK., Bagel J; Psoriasis Treatment Center of New Jersey, East Windsor, NJ, USA., Armstrong AW; University of California Los Angeles, Los Angeles, CA, USA., Gooderham M; SKiN Centre for Dermatology, Peterborough, Queen's University, Kingston, and Probity Medical Research, Waterloo, ON, Canada., Strober B; Yale University School of Medicine, New Haven, and Central Connecticut Dermatology Research, Cromwell, CT, USA., Thaçi D; Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany., Morita A; Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan., Imafuku S; Faculty of Medicine, Fukuoka University Hospital, Fukuoka, Japan., Foley P; The University of Melbourne, Parkville, St. Vincent's Hospital Melbourne, Fitzroy, and Probity Medical Research and Skin Health Institute, Carlton, VIC, Australia., Sofen H; University of California Los Angeles, Los Angeles, CA, USA.; Dermatology Research Associates, Los Angeles, CA, USA., Zheng M; The Second Affiliated Hospital and Zhejiang University School of Medicine, Hangzhou, China., Hippeli L; Bristol Myers Squibb, Princeton, NJ, USA., Kisa RM; Bristol Myers Squibb, Princeton, NJ, USA., Banerjee S; Bristol Myers Squibb, Princeton, NJ, USA., Blauvelt A; Oregon Medical Research Center, Portland, OR, USA.

Publikováno v: The Journal of dermatological treatment [J Dermatolog Treat] 2024 Dec; Vol. 35 (1), pp. 2371045. Date of Electronic Publication: 2024 Jun 30.

Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).

Autor: Strober B; Department of Dermatology, Yale University, New Haven, Connecticut, USA.; Central Connecticut Dermatology Research, Cromwell, Connecticut, USA., Blauvelt A; Oregon Medical Research Center, Portland, Oregon, USA., Warren RB; Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UK.; Manchester NIHR Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK., Papp KA; Alliance Clinical Trials and Probity Medical Research, Waterloo, Ontario, Canada.; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Armstrong AW; Department of Dermatology, University of California Los Angeles, Los Angeles, California, USA., Gordon KB; Dermatology - Froedtert Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Morita A; Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan., Alexis AF; Department of Dermatology, Weill Cornell Medicine, New York, New York, USA., Lebwohl M; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Foley P; Skin Health Institute and Probity Medical Research, Melbourne, Victoria, Australia., Kisa RM; Bristol Myers Squibb, Princeton, New Jersey, USA., Colston E; Bristol Myers Squibb, Princeton, New Jersey, USA., Wang T; Bristol Myers Squibb, Princeton, New Jersey, USA., Banerjee S; Bristol Myers Squibb, Princeton, New Jersey, USA., Thaçi D; Institute and Comprehensive Centre for Inflammation Medicine, University of Luebeck, Luebeck, Germany.

Publikováno v: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2024 Aug; Vol. 38 (8), pp. 1543-1554. Date of Electronic Publication: 2024 Mar 07.

Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.

Autor: Thaçi D; Institute and Comprehensive Center for Inflammation Medicine, University of Luebeck, Ratzeburger Allee 160, 23538, Luebeck, Germany. diamant.thaci@uksh.de., Strober B; Yale University, Central Connecticut Dermatology Research, New Haven, CT, USA., Gordon KB; Medical College of Wisconsin, Milwaukee, WI, USA., Foley P; St Vincent's Hospital Melbourne, Probity Medical Research, Skin Health Institute, The University of Melbourne, Melbourne, VIC, Australia., Gooderham M; SKiN Centre for Dermatology, Queen's University and Probity Medical Research, Peterborough, ON, Canada., Morita A; Nagoya City University, Graduate School of Medical Sciences, Nagoya, Aichi, Japan., Papp KA; Clinical Research and Probity Medical Research, Waterloo, ON, Canada., Puig L; Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain., Menter MA; Baylor University Medical Center, Dallas, TX, USA., Colombo MJ; Bristol Myers Squibb, Princeton, NJ, USA., Elbez Y; Bristol Myers Squibb, Princeton, NJ, USA., Kisa RM; Bristol Myers Squibb, Princeton, NJ, USA., Ye J; Bristol Myers Squibb, Princeton, NJ, USA., Napoli AA; Bristol Myers Squibb, Princeton, NJ, USA., Wei L; Bristol Myers Squibb, Princeton, NJ, USA., Banerjee S; Bristol Myers Squibb, Princeton, NJ, USA., Merola JF; Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA., Gottlieb AB; Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Publikováno v: Dermatology and therapy [Dermatol Ther (Heidelb)] 2022 Feb; Vol. 12 (2), pp. 495-510. Date of Electronic Publication: 2022 Jan 13.